Shanghai HeartCare Medical Technology (HKSE:06609) Total Inventories : HK$159.7 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology Total Inventories?

Shanghai HeartCare Medical Technology's total inventories for the quarter that ended in Dec. 2023 was HK$159.7 Mil. Shanghai HeartCare Medical Technology's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was HK$167.2 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Shanghai HeartCare Medical Technology's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$20.45.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Shanghai HeartCare Medical Technology's Days Inventory for the six months ended in Dec. 2023 was 720.66.

Inventory Turnover measures how fast the company turns over its inventory within a year. Shanghai HeartCare Medical Technology's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.25.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Shanghai HeartCare Medical Technology's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 1.25.

Shanghai HeartCare Medical Technology Total Inventories Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology Total Inventories Chart

Shanghai HeartCare Medical Technology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

0.28

10.24

39.34

147.58

159.73

Shanghai HeartCare Medical Technology Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial				39.34	78.01	147.58	174.72	159.73

Shanghai HeartCare Medical Technology Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Shanghai HeartCare Medical Technology (HKSE:06609) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Shanghai HeartCare Medical Technology's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(788.767	+	0.75 * 84.126	+	0.5 * 159.734	-	137.38
-	0	-	0)	/	38.8344
=	20.45

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Shanghai HeartCare Medical Technology's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	167.2255	/	42.348	*	365 / 2
	=	720.66

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Shanghai HeartCare Medical Technology's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	42.348	/	167.2255
	=	0.25

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Shanghai HeartCare Medical Technology's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	167.2255	/	134.27
	=	1.25

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Shanghai HeartCare Medical Technology Total Inventories Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai HeartCare Medical Technology (HKSE:06609) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN

Website

http://www.strokemedical.com

Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.

Executives

Ding Kui	2201 Interest of corporation controlled by you
Wisary Limited	2101 Beneficial owner
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology (HKSE:06609) Headlines

No Headlines